Acadia (ACAD) PT Lowered to $30 at Needham & Company, Keeps 'Buy' as News Was Mostly Expected
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $30.00 (from $44.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
